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Abstract: Adiposis dolorosa (AD) is a rare disorder of painful nodular subcutaneous fat 
  accompanied by fatigue, difficulty with weight loss, inflammation, increased fluid in   adipose   tissue 
(lipedema and lymphedema), and hyperalgesia. Sequential compression relieves   lymphedema 
pain; we therefore hypothesized that whole body cyclic pneumatic hypobaric compression 
may relieve pain in AD. To avoid exacerbating hyperalgesia, we utilized a touch-free method, 
which is delivered via a high-performance altitude simulator, the Cyclic Variations in Altitude 
ConditioningTM (CVACTM) process. As a pilot study, 10 participants with AD completed pain and 
quality of life questionnaires before and after 20–40 minutes of CVAC process daily for 5 days. 
Participants lost weight (195.5  ± 17.6–193.8 ± 17.3 lb; P = 0.03), and bioimpedance significantly 
decreased (510 ± 36–490 ± 38 ohm; P = 0.01). There was a significant decrease in scores on 
the Pain Catastrophizing Scale (P = 0.039), in average (P = 0.002), highest (P = 0.029), lowest 
(P = 0.04), and current pain severity (P = 0.02) on the Visual Analogue Scale, but there was no 
change in pain quality by the McGill Pain Questionnaire. There were no significant changes in 
total and physical SF-36 scores, but the mental score improved significantly (P = 0.049). There 
were no changes in the Pain Disability Index or Pittsburgh Sleep Quality Index. These data 
present a potential, new, noninvasive means of treating pain in AD by whole body pneumatic 
compression as part of the CVAC process. Although randomized, controlled trials are needed 
to confirm these data, the CVAC process could potentially help in treating AD pain and other 
chronic pain disorders.
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Introduction
Adiposis dolorosa (AD) is considered a rare disorder by the National Institutes of Health 
and the National Organization for Rare Disease; in Lund, Sweden, 0.1% of the popula-
tion is affected.1 The pain associated with AD is in subcutaneous fat, but patients also 
complain of fatigue, cognitive changes, sleep disturbance, shortness of breath, rapid heart 
rate, gastrointestinal complaints, and myalgias and arthralgias. Hyperalgesia is prominent, 
similar to signs and symptoms associated with fibromyalgia,2 but with the difference that 
the physical examination is greatly abnormal in AD compared with essentially normal 
in fibromyalgia. The pain in AD varies in intensity and type, can occur in flares, and is 
associated with inflammation3 and fluid in adipose tissue called lipedema,4 which can 
progress to lymphedema; seroma formation is common after adipose resection.3,4
Current treatments for AD include surgical excision or liposuction,5–7   intravenous 
lidocaine,8 topical analgesics,9,10 infliximab and methotrexate,11 and pregabalin com-
bined with manual lymphatic drainage therapy.12 Intravenous lidocaine is not effective Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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for many patients with AD; topical analgesics provide modest 
relief; and the   immunosuppressive   combination of infliximab 
and methotrexate risks   complications, such as infection, and 
has only shown benefit in a single case to date. External pneu-
matic compression is known to relieve pain associated with 
edema.13,14 Although whole body external pneumatic compres-
sion is available,15 the neck and head are not treated raising a 
concern for increasing fluid in these areas and exacerbating 
the fatigue, cognitive changes, and sleep disturbances in AD. 
Manual lymphatic drainage is also effective for pain relief 
in AD;12 however, only small areas of the body can be treated 
at a time. In addition, individuals with AD may not tolerate 
external compression because of hyperalgesia.
The Cyclic Variations in Altitude Conditioning™ (CVAC) 
(CVAC Systems, Inc; Temecula, California, USA) process is 
an alternative and potentially revolutionary method of touch-
free cyclic hypobaric pneumatic compression for treatment 
of tissue edema and, therefore, edema-associated pain. Dur-
ing the CVAC process, an individual sits within the CVAC 
altitude simulator while pressure cycles 300 to 500 times in a 
session simulating altitudes up to 3,200 m. At higher altitude 
levels (up to 6,858 m), the dynamic change in hypobaric pres-
sure over a larger range of altitudes provides an intermittent 
hypobaric hypoxic experience. The CVAC process has been 
shown to improve blood oxygen saturation up to 6% by pulse 
oximetry, consistent with a rapid, enduring, and beneficial 
altitude response.16 We hypothesized that the CVAC process 
would improve pain and quality of life in AD patients as 
measured by validated questionnaires.
Materials and methods
Participants
Ten consecutive participants were recruited and completed 
the study with no dropouts. The average age of the 4 men 
and 6 women in the study was 48 ± 3.6 years ranging from 
31 to 72 years (Table 1). All participants were Caucasian 
and nonHispanic with the exception of 1 male Hispanic. 
The average weight was 88.7 ± 8 kg, and the body mass 
index was 28.3 ± 1.8 kg/m2. The majority of subjects took 
multiple medications and had additional comorbidities. Half 
of the subjects carried a diagnosis of fibromyalgia.
Study protocol
AD is a rare disorder; therefore, the number of affected 
  participants in a given area may be small. This study was 
limited to individuals with AD interested in research, in our 
  database within the local area or those requesting   participation 
in research who were from out of town and could travel and 
stay for the week-long study. This study was approved by the 
Institutional Review Board at the University of California, 
San Diego (UCSD) and by the Veterans Affairs San Diego 
Healthcare System (VASDHS) Research and   Development 
Table 1 Demographics, medications, and comorbidities of participants with AD
Subject no. Sex Age Medications Comorbidities
1 M 46 Aspirin; eszopiclone; famotidine; loratidine;  
metoprolol; omeprazole; tramadol; valsartan
Esophageal candidiasis; gastritis; HTN; lipoma  
resection
2 F 56 Alprazolam; cephalexin; cyclobenzaprine; diazepam;  
duloxetine; hydroxyzine; modafinil; opioid; narcotic;  
pantoprazole; zolpidem
Achilles tendon repair; familial multiple lipomatosis; 
lipedema; lipolymphedema; morbid obesity;  
total knee replacement
3 M 37 Medical marijuana; opioid; narcotic Fibromyalgia
4 F 36 None Fibromyalgia; hysterectomy; lipoma resection; 
pseudotumor cerebri
5 F 39 Zolpidem Adipose liposuction; endometriosis; IBS; insomnia; 
lipoma resection; Raynaud’s disease
6 F 59 Aripiprazole; lidocaine gel; lovastatin; omeprazole;  
opioid; narcotic; pregabalin
Depression; fibromyalgia; GERD; dyslipidemia; bilateral   
TMJ surgery
7 M 51 Carbamazepine; gabapentin; metformin;  
opioid narcotic; temazepam; testosterone;  
venlafaxine; warfarin; zonisamide
Cognitive dysfunction; depression; familial 
multiple lipomatosis; fibromyalgia; hypogonadism; 
hypovitaminosis D; insomnia
8 M 47 Cetirizine; lorazepam; omeprazole Environmental allergies; familial multiple lipomatosis
9 F 72 Allopurinol; amlodipine; aspirin;  
colchicine; lorazepam; metoprolol; sucralfate;  
triamterene – hydrochlorthiazide
Chronic back pain; Dupuytren’s contracture; 
dyslipidemia; HTN; osteoarthritis
10 F 48 Aldactone; alprazolam amphetamine;  
celecoxib; cyclobenzaprine; duloxetine;  
levothyroxine; opioid narcotics; olmesartan; tramadol
Anxiety; cognitive dysfunction; depression; fibromyalgia;  
hypothyroidism; IBS; insomnia; obstructive sleep apnea
Abbreviations:  AD,  adiposis  dolorosa;  HTN,  hypertension;  IBS,  irritable  bowel  syndrome;  GERD,  gastroesophageal  reflux  disease;  TMJ,  temporomandibular  joint;   
M, male; F, female.Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
149
Cycling hypobaric pressure improves pain in AD
Committee. All participants provided written and informed 
consent prior to participation. Subject visits were at the   Center 
for Metabolic Research as part of the Special   Diagnostic and 
Treatment Unit at the VASDHS. Participants were enrolled 
if they had a diagnosis of AD (confirmed by 1 of the authors, 
KLH). Anecdotal data suggested that more than one 20-minute 
CVAC process exposure beyond the acclimation phase (day 1) 
was required for a change in pain; therefore, we chose 5 days 
of CVAC process exposures for this protocol (CVAC Systems, 
Inc, pers comm). After consent, participants were weighed, 
and completed questionnaires then underwent the first CVAC 
process (total of 25 minutes). On days 2–5, participants were 
exposed to the CVAC process   during two 20-minute sessions. 
On day 5, participants repeated questionnaires and received 
the final two 20-minute CVAC process exposures.
CVAC process sessions
The dynamic whole body cyclic pneumatic compression 
was administered using a high-performance altitude simula-
tor. Participants sit in the simulator that has a large window 
resembling the canopy windshield of a fighter jet. The CVAC 
process exposes individual users to various   simulated alti-
tudes arranged into precise patterns. Each session consists of 
between 300 and 500 cyclic altitude changes in a 20-minute 
period with an average rate of change of 30.5 m/s and an 
approximate cumulative change of 365,760 m in a 20-minute 
session. A proprietary robotic system controls pressure 
changes within the simulator, whereas the open system pre-
vents carbon dioxide build-up. The dynamic changes result 
in a pulsatile effect of pressure; at altitudes above 3,200 m 
(not in this study protocol), there is also a pulsatile effect on 
oxygen saturation in the blood.16 Examples of these dynamic 
changes have been published previously.16 Participants were 
instructed how to equalize pressures in their ears using the 
jaw jack, the Valsalva maneuver, and side-to-side neck exten-
sion as the Eustachian tubes change shape with changing 
pressures. For this study, on day 1, participants were initially 
exposed to the CVAC process in 5 stages (Tier 1; #1–5) of 5 
minutes’ duration each. The maximal altitude for this Tier 1 
stage is 3,200 m. On each subsequent day, participants were 
given a maximum of two 20-minute sessions on Tier 2, with 
a maximum altitude also of 3,200 m.
Bioelectrical impedance analysis
Bioelectrical impedance analysis (BIA) measurements 
were taken by using the Tanita® leg-to-leg system (model 
TBF–300A; Arlington Heights, Illinois, USA). The 
Tanita analyzer measures lower-body resistance between 
the right and the left legs as the individual stands on the 
  electrode plates of the analyzer. During the 5-day protocol, 
  participants were measured at the same time each morning 
after   emptying the bladder, and while standing erect, in bare 
feet, on the analyzer’s footpads wearing street clothes or a 
gown. The system’s 2 electrodes are in the form of stainless 
steel   footpads. Leg-to-leg impedance and body mass are 
simultaneously measured as the subject’s bare feet make 
pressure contact with the electrodes and digital scale. The 
body fat monitor or analyzer automatically measures weight 
and then impedance. Computer software (a microprocessor) 
imbedded in the product uses the measured impedance, the 
subject’s gender, height, fitness level and age, which have 
been preprogrammed, and the weight to determine body fat 
percentage based on equation formulas. Through multiple 
regression analysis, Tanita has derived standard formulas 
to determine body fat percentage. Tanita’s equations are 
generalized for standard adults and athletes. The technology 
determines the electrical impedance of body tissues, which 
provides an estimate of total body water (TBW). Using these 
values of TBW derived from BIA, fat-free mass (FFM) and 
body fat may then be estimated. The standard error of esti-
mate or prediction error for BIA is about 3.5%.17
Questionnaires
On days 1 and 5 of the study, participants completed measures 
of pain severity (McGill Pain Questionnaire),18 pain-related 
symptoms (Pain Catastrophizing Scale [PCS]19 and Pain 
  Disability Index [PDI]), and quality of life (the Pittsburgh 
Sleep Quality Index [PSQI]20 and SF-36).   Participants 
  completed the Visual Analogue Scale (VAS) as a daily measure 
of pain severity. We selected the above questionnaires based on 
the criteria of being validated instruments, widely used in stud-
ies of chronic pain patients, that captured the spectrum of pain 
intensity, and the functional aspects of pain believed to poten-
tially improve as a result of the CVAC process exposures.
The McGill Pain Questionnaire is a widely used mea-
sure assessing the quality and intensity of pain. The VAS is 
a single-item measure wherein respondents rate their pain 
intensity on a 0–10 scale, with 0 indicating no pain and 10 
representing the worst pain imaginable. The PCS is a 13-item 
questionnaire assessing pain perceptions in the areas of 
rumination, magnification, and helplessness. Higher scores 
indicate a greater tendency to catastrophize pain symptoms. 
The PDI is a 7-item instrument that quantifies the impact 
of pain on the respondent in areas of living including fam-
ily, recreation, social, occupational, sexual, self-care, and 
life support activities. The PSQI was developed to measure Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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sleep quality during the previous month covering domains 
  including subjective sleep quality, sleep latency, sleep dura-
tion, habitual sleep efficiency, sleep disturbances, use of sleep 
medications, and daytime dysfunction. Finally, the SF-36 is 
a multidimensional health survey yielding an overall func-
tional health score and separate physical and mental health 
dimension scores.
Data analyses
Data are presented as average ± standard error of the mean. 
Statistical analyses consisted of repeated measures analysis 
of variance (ANOVA) models to compare mean changes 
between day 1 and day 5 on the measured pain,   psychosocial, 
and metabolic indices. For the VAS data, wherein pain scores 
were available for each of the 5 participation days, we used 
repeated measures ANOVA to assess trends in average, 
high, and low pain scores across the length of the study pro-
tocol. In each of the 3 VAS repeated measures models, we 
assessed the assumption of sphericity using Mauchly’s test. 
This assumption was met in all cases. These analyses were 
performed using GraphPad Prism version 5.00 (GraphPad 
Software; San Diego, California, USA) for Windows. For the 
purpose of some of the graphical illustrations, we depicted 
results in units of percent changes, calculated as the absolute 
mean difference in day 1 vs day 5 divided by the day 1 mean 
([D1–D5]/D1). A P value of 0.05 was used as the criterion 
for declaring statistical significance.
Results
CVAC process
The average number of CVAC sessions completed during 
days 1–5 was 9.4 ± 0.5. One participant was able to complete 
only 1 session daily due to difficulty in equilibrating ear 
pressure. Another completed only 8 sessions for the same 
reason. No side effects occurred.
Questionnaires
A comparison of pre-CVAC vs post-CVAC process exposures   
McGill Pain Questionnaire scores indicated a significant 
decrease in participant’s current pain severity (3.1 ± 0.3 to 
2.0 ± 0.2 from a total of 5; P = 0.02), but no change in rat-
ings of pain quality or in worst and least pain reports (Figure 
1). Scores on the PCS also significantly decreased on day 5 
compared with day 1 (28.2 ± 3.5 to 25.2 ± 2.9; P = 0.039). 
Undergoing the CVAC process also resulted in significantly 
reduced average (5.6 ± 0.6 to 4.2 ± 0.6; P = 0.002), highest 
(7 ± 0.7 to 5.7 ± 0.7; P = 0.029), and lowest pain (4.4 ± 0.5 
to 3.4 ± 0.4; P = 0.043) levels on day 5 compared with day 1. 
A trend analysis for the daily average VAS data indicated   
significant linear (overall decrease across the 5 days; 
P = 0.002) and quadratic (flatter means in first days of pain 
reports followed by larger decreases later; P = 0.013) patterns 
of changes over 5 days (Figure 1). There was a significant 
linear (P = 0.043) but not quadratic decrease for highest 
pain by the VAS over 5 days, and again a significant linear 
(P = 0.028) and quadratic (P = 0.03) pattern of decreases were 
evident in lowest experienced pain over 5 days on the VAS. 
There was no change in the overall SF-36 score or physical 
functioning, but mental functioning increased significantly 
(32.8 ± 4.8 to 38.8 ± 4.7; P = 0.049). There were no significant 
changes in the PDI or PSQI on day 5 compared with day 1 
(data not reported). Data from the study questionnaires are 
illustrated in Figure 1.
Weight and BIA
Subject weight significantly decreased from day 1 to day 5 
(88.7 ± 8 to 87.8 ± 7.8 kg; P = 0.03; Figure 1). Although there 
was a nonsignificant increase in percent fat (32.4 ± 3.4% to 
35.4 ± 3.7%) and total fat mass (27.2 ± 3.9 to 32.9 ± 6.2 kg), 
there was a trend to decrease FFM (55 ± 3.8 vs 54.9 ± 3.3 kg; 
P = 0.053) by BIA. Bioimpedance decreased significantly 
from 510 ± 36 to 490 ± 38 ohm (P = 0.014; Figure 1) with 
no significant change in calculated TBW (40.8 ± 2.6 to 
41.4 ± 2.6 kg).
Discussion
We demonstrated that changing air pressure around participants 
with AD from ambient altitude (about 60 m above sea level 
in San Diego, California, USA) to 3,200 m, 300–500 times 
in a 20-minute session, for up to 2   sessions daily (total of 40 
minutes), over 5 days significantly reduced pain   perceptions 
and intensity. The average altitude for the sessions over the 
5-day period was approximately 1,828 m. This pneumatic 
compression benefit on pain reports manifested across several 
distinct measures including   VAS-measured pain intensity, 
lower current pain levels as captured by the McGill Pain 
Questionnaire, reduced tendencies to catastrophize pain 
symptoms on the PCS, and greater quality of life as indicated 
by improved mental health   function scores on the SF-36. 
Given that both the pain patterns on the average and the low 
VAS scores had significant linear and quadratic changes, our 
data suggest that pain changes really did not manifest until 
day 3 or 4. These data could infer that a 1-day CVAC process 
intervention would not be sufficient to alter pain status. On 
the contrary, we saw no evidence of pain scores leveling off 
during days 4–5, so an even longer CVAC protocol might Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
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yield additional benefits. Although these results are limited by 
the small sample, short-term treatment, and nonrandomized 
design of this pilot study, the observation that widespread 
pain-related benefits can be achieved in a brief CVAC process 
intervention is supportive of further research attention to this 
novel treatment for AD.
At least 3 potential mechanisms may account for the 
observed improvements in pain reports in this study. First, 
tissue edema likely decreased, as supported by a significant 
decrease in weight in participants and a significant decrease 
in impedance; a decrease in impedance indicates less water 
in tissue. The multiple changes in external pressure during 
the CVAC process exposure may cause the lymph fluid to 
move out of the tissue similar to external compression;21 
this pneumatic displacement of fluid improves pain in lym-
phedema.22 Another possible mechanism to explain improved 
pain in participants with AD could be through improved blood 
flow by the intermittent pneumatic compression,23 consistent 
with the CVAC process; this could allow for a secondary 
decrease in tissue edema. The CVAC process has also been 
demonstrated to increase arterial oxygen saturation.16 Muscle 
contraction improving lymph flow and oxygenation also 
occurs with exercise.24 Pain in lipedema is thought to result 
from hypoxia, inflammation, and necrosis of adipocytes;25 
therefore, improved blood flow and oxygen saturation may 
decrease hypoxia in the painful adipose tissue.26 If these 
mechanistic theories are confirmed, the CVAC process may 
also hold treatment potential for other chronic pain condi-
tions in which impaired blood flow and tissue edema are 
contributing factors. For example, improved blood flow may 
be a mechanism through which exercise improves pain and 
quality of life among fibromyalgia patients.27 To date, how-
ever, the CVAC process has not been tested in fibromyalgia 
populations, although 5 of 10 participants in this study had 
a diagnosis of fibromyalgia. Future work could focus on 
pain relief after CVAC process exposure compared with 
exercise or combined with exercise. Pain pathways could 
also be assessed systematically as they relate to pneumatic 
compression or exercise.
In contrast to our observations of consistently favorable 
changes in pain reports following the 5-day CVAC process 
intervention, there was no evidence to suggest improvements 
in areas of pain disability, sleep, or physical function from 
this protocol. Although it is possible that the lack of improve-
ment in these areas represents limitations in CVAC process 
treatment, an alternative interpretation is that the absence of 
changes in the latter dimensions was a result of the brevity 
of the intervention. A longer measurement protocol may 
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be required in order to assess the potential for meaningful 
change in the areas of sleep quality and quantity, family, 
social and sexual relationships, occupational functioning, and 
self-care. Additional research will be required to compare 
the merits of these interpretive hypotheses.
We also observed some preliminary evidence for CVAC 
process-induced body weight changes as measured by bio-
impedance technology. Weight significantly decreased for 
the participants in this pilot study over 5 days. Interestingly, 
although weight significantly decreased after CVAC process 
exposures, fat mass and fat percent increased and FFM signifi-
cantly decreased as measured by BIA. Bioimpedance analysis 
is a widely used method to estimate body composition. When a 
current is passed through the body, the water-containing tissues 
primarily conduct the electrical current so that impedance 
is higher with increased FFM, which is 73% hydrated;28,29 
impedance is also increased in lymphedema.30 In other words, 
impedance increases with increased water in tissues. In BIA, 
higher TBW results in a measure of lower body fat percentage; 
less water increases the percentage of body fat and decreases 
calculated FFM. There is currently no algorithm for BIA that 
provides a volume in liters.29 In our participants, although 
weight significantly decreased after CVAC process expo-
sures, fat mass and fat percent increased and FFM decreased 
consistent with a significant decrease in impedance. These 
data suggest that the CVAC process decreases tissue fluid 
in AD accounting for a significant decrease in weight loss. 
The CVAC process of gentle pneumatic compression cycled 
300–500 times in a 20-minute period repeated on an average 
of 9 times in 1 week, therefore, decreased tissue fluid weight in 
our participants with AD while decreasing pain. These changes 
in BIA measures would best be confirmed by the use of dual 
X-ray absorptiometry for body composition, perometry for 
limb volume measurements, and deuterium isotope dilution as 
a measure of TBW before and after the CVAC process.
In conclusion, the CVAC process, which is touchless, 
cycled, pneumatic, hypobaric compressions administered via 
a high-performance altitude simulator, may decrease tissue 
fluid and improve oxygen saturation resulting in decreased 
pain in people with AD. Although randomized, controlled 
trials are needed to confirm these data, the CVAC process 
could potentially help in treating AD, related chronic pain 
disorders, and painful lipedema.
Acknowledgments
The authors thank Phil Peck, Torri Middlebrooks, and Amanda 
Wirtz for conducting CVAC sessions; the Center for Meta-
bolic Research in the VASDHS for the use of their facilities; 
and CVAC Systems, Inc, for the use of the CVAC altitude 
simulator. The UCSD General Clinical Research Center and 
the NIDDK supported KLH by Public Health Grant 5M01 
RR000827and grant K23 DK 065038-05, respectively.
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  Brorson H, Fagher B. Dercum’s disease. Fatty tissue rheumatism caused 
by immune defense reaction? Lakartidningen. 1996;93(15):1430, 
1433–1436.
  2.  Stormorken H, Brosstad FHS. The fibromyalgia syndrome: A   member 
of the painful lipomatosis family? In: Pederson JA, editor. New 
Research on Fibromyalgia. New York: Nova Science Publishers; Inc; 
2006.
  3.  Herbst KL, Asare-Bediako S. Adiposis Dolorosa is more than painful 
fat. Endocrinologist. 2007;17(6):326–344.
  4.  Dercum FX. A subcutaneous connective-tissue dystrophy of the arms 
and back, associated with symptoms resembling myxoedema. Univ 
Med Mag Philadelphia. 1888;1:140–150.
  5.  Berntorp E, Berntorp K, Brorson H, Frick K. Liposuction in Dercum’s 
disease: impact on haemostatic factors associated with   cardiovascular 
disease and insulin sensitivity. J Intern Med. 1998;243(3):197–201.
  6.  Brorson H, Aberg M, Fagher B. Liposuction in adiposis dolorosa 
(morbus Dercum) – an effective therapy. Ugeskr Laeger. 1992;154(27): 
1914–1915.
  7.  DeFranzo AJ, Hall JH Jr, Herring SM. Adiposis dolorosa (Dercum’s 
disease): liposuction as an effective form of treatment. Plast Reconstr 
Surg. 1990;85(2):289–292.
  8.  Petersen P, Kastrup J. Dercum’s disease (adiposis dolorosa). Treatment of 
the severe pain with intravenous lidocaine. Pain. 1987;28(1):77–80.
  9.  Desai MJ, Siriki R, Wang D. Treatment of pain in Dercum’s dis-
ease with Lidoderm (lidocaine 5% patch): a case report. Pain Med. 
2008;9(8):1224–1226. Epub 2008 Mar 11.
  10.  Reggiani M, Errani A, Staffa M, Schianchi S. Is EMLA effective in 
Dercum’s disease? Acta Derm Venereol. 1996;76(2):170–171.
  11.  Singal A, Janiga J, Bossenbroek N, Lim H. Dercum’s disease (adiposis 
dolorosa): a report of improvement with infliximab and methotrexate. 
J Eur Acad Dermatol Venereol. 2007;21(5):717.
  12.  Lange U, Oelzner P, Uhlemann C. Dercum’s disease (Lipomatosis 
dolorosa): successful therapy with pregabalin and manual lymphatic 
drainage and a current overview. Rheumatol Int. 2008;29(1):17–22. 
Epub 2008 Jul 5.
  13.  Hamner JB, Fleming MD. Lymphedema therapy reduces the volume 
of edema and pain in patients with breast cancer. Ann Surg Oncol. 
2007;14(6):1904–1908. Epub 2007 Mar 8.
  14. Tamir L, Hendel D, Neyman C, Eshkenazi AU, Ben-Zvi Y, 
Zomer R. Sequential foot compression reduces lower limb swelling 
and pain after total knee arthroplasty. J Arthroplasty. 1999;14(3): 
333–338.
  15.  Morris RJ. Intermittent pneumatic compression – systems and applica-
tions. J Med Eng Technol. 2008;32(3):179–188.
  16.  Hetzler RK, Stickley CD, Kimura IF, et al. The effect of dynamic inter-
mittent hypoxic conditioning on arterial oxygen saturation. Wilderness 
Environ Med. 2009;20(1):26–32.
  17.  Heymsfield SB, Wang Z, Visser M, Gallagher D, Pierson RN Jr. 
  Techniques used in the measurement of body composition: an overview 
with emphasis on bioelectrical impedance analysis. Am J Clin Nutr. 
1996;64 Suppl 3:S478–S484.
  18.  Melzack R. The McGill pain questionnaire: from description to 
  measurement. Anesthesiology. 2005;103(1):199–202.
  19.  Sullivan MJL, Bishop S, Pivik J. The pain catastrophizing scale: 
  development and validation. Eur J Psychol Assess. 1995;7:524–532.Journal of Pain Research
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/journal-of-pain-research-journal
The Journal of Pain Research is an international, peer-reviewed, open 
access, online journal that welcomes laboratory and clinical findings 
in the fields of pain research and the prevention and management 
of pain. Original research, reviews, symposium reports, hypoth-
esis formation and commentaries are all considered for publication.   
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
153
Cycling hypobaric pressure improves pain in AD
  20.  Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The 
Pittsburgh Sleep Quality Index: a new instrument for psychiatric   practice 
and research. Psychiatry Res. 1989;28(2):193–213.
  21.  McGeown JG, McHale NG, Thornbury KD. The role of external 
  compression and movement in lymph propulsion in the sheep hind 
limb. J Physiol. 1987;387:83–93.
  22.  Yamazaki Z, Idezuki Y, Nemoto T, Togawa T. Clinical experiences using 
pneumatic massage therapy for edematous limbs over the last 10 years. 
Angiology. 1988;39(2):154–163.
  23.  Delis KT, Labropoulos N, Nicolaides AN, Glenville B, Stansby G. 
Effect of intermittent pneumatic foot compression on popliteal artery 
haemodynamics. Eur J Vasc Endovasc Surg. 2000;19(3):270–277.
  24.  Havas E, Parviainen T, Vuorela J, Toivanen J, Nikula T, Vihko V . Lymph 
flow dynamics in exercising human skeletal muscle as detected by 
scintography. J Physiol. 1997;504(Pt 1):233–239.
  25.  Fife CE, Maus EA, Carter MJ. Lipedema: a frequently misdiagnosed 
and misunderstood fatty deposition syndrome. Adv Skin Wound Care. 
2010;23(2):81–92; quiz 93–84.
  26.  Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin 
resistance. Int J Obes (Lond). 2009;33(1):54–66.
  27.  Fontaine KR, Conn L, Clauw DJ. Effects of lifestyle physical activity on 
perceived symptoms and physical function in adults with fibromyalgia: 
results of a randomized trial. Arthritis Res Ther. 2010;12(2):R55.
  28.  Cornish B. Bioimpedance analysis: scientific background. Lymphat Res 
Biol. 2006;4(1):47–50.
  29.  Earthman C, Traughber D, Dobratz J, Howell W. Bioimpedance 
  spectroscopy for clinical assessment of fluid distribution and body cell 
mass. Nutr Clin Pract. 2007;22(4):389–405.
  30.  Warren AG, Janz BA, Slavin SA, Borud LJ. The use of bioimpedance 
  analysis to evaluate lymphedema. Ann Plast Surg. 2007;58(5):541–543.